Skip to main content
OpenTrials
Completed

NCT Number: NCT04842929

Magnetic Randomized Trial in Elderly Depressed

Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness, adverse effects and drug interactions, especially in the elderly population. In this context, the investigators investigate a non-pharmacological treatment known as recurrent transcranial magnetic stimulation (rTMS) with the theta-burst stimulation (TBS) method for the treatment of geriatric depression. This treatment modality has almost no adverse effects and avoids the risk associated with polypharmacy, providing an interesting alternative to antidepressant treatments. Our aim is to evaluate TBS efficacy in the treatment of geriatric depression in a randomized, double-blind, placebo-controlled clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Sao Paulo

São Paulo, Brazil

About this study

Recurrent transcranial magnetic stimulation (rTMS) is a consolidated procedure for the treatment of depression, with several meta-analyzes demonstrating its efficacy. The theta-burst stimulation (TBS) method is a modification of the usual rTMS protocol. As a new protocol, there are still few studies evaluating its efficacy in treatment of major depression, although a recently published meta-analysis has pointed to benefits of this therapeutic modality. To date, there are no studies published with this method for the treatment of geriatric depression. This study will be a randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of theta-burst rTMS in the treatment of major depressive disorder in the elderly, randomizing 108 subjects to the experimental (TBS) and comparative (sham) groups. The coil will be positioned in the dorsolateral prefrontal cortex, with intermittent TBS (iTBS, stimulatory) mode on the left and continuous TBS (cTBS, inhibitory) on the right. Stimulation protocol consists of 1800 pulses on each brain hemisphere, totaling a ten minutes session. There will be 20 consecutive sessions, one a day, except on weekends and holidays. The cycle of continuous intervention will last approximately four weeks, after which applications with the same technique will be performed at the end of weeks 6, 8 and 12. Clinical outcome measures will be obtained on eight occasions: treatment baseline, and after 1, 2, 4, 6, 8 and 12 weeks of onset. The main clinical outcome will be measured using the Hamilton Depression Scale (HDRS), comparing baseline scores with those obtained after 6 weeks of treatment. As secondary endpoints, we will use the Global Clinical Impression Scale (CGI), the CIRS (Cumulative Illness Rating Scale), the Geriatric Depression Scale (GDS), the intermediate scores obtained on the HDRS scale, the Positive and Negative Affect Scale (PANAS), the Montgomery-Asberg Depression Rating Scale (MADRS), and variations in serum BDNF concentrations; all these evaluation tools have validated versions in Portuguese. As tolerability and safety parameters, the incidence of adverse events and the occurrence of manic/hypomanic symptoms will be evaluated by the Young Mania Scale (YMRS). TBS stimulation will be evaluated in terms of safety, tolerability and effectiveness for the treatment of major depression in the elderly, possibly becoming another therapeutic option useful for patients with poor response or contraindications to the use of antidepressants.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major Depressive Disorder;
  • Patients older than 60 years
  • Hamilton equal or higher than 17

Exclusion criteria

  • Other mental disorders (alcohol or drug addiction, psychotic disorders, dementia, bipolar disorder);
  • Presence of serious neurological or clinical diseases;
  • Resence of severe suicidal ideation and CIRS (Cumulative Illness Rating Scale) score> 7, characterizing a set of clinical morbidities that could impair adherence to the research protocol, bipolar disorder and/or presence of manic symptoms (hypo) demonstrated with more than 8 points in the Young Mania Rating Scale.
  • Metal implants;
  • Epilepsy or electronics in the cephalic segment;

Treatment and study plan

Transcranial Magnetic Stimulation

Device

The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.

Primary outcomes

  1. Changes in Hamilton Rating Scale for Depression, 17 items (HDRS-17)

    Time frame: Weeks 0 and 6

    Continuous measure (score changes).

Secondary outcomes

  1. Change in HDRS-17

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  2. Change in Montgomery-Asberg Depression Rating Scale (MADRS)

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  3. Change in Global Clinical Impression Scale (CGI)

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  4. Change in Cumulative Illness Rating Scale (CIRS)

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  5. Change in Geriatric Depression Scale (GDS)

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  6. Change in Positive and Negative Affect Scale (PANAS)

    Time frame: Weeks 1, 2, 4, 6, 8, 12

    Continuous measure (score changes).

  7. Change in serum BDNF concentrations

    Time frame: Weeks 0 and 6

    Continuous measure (score changes).

  8. Response HDRS 17

    Time frame: Week 12

    Response (≥50% improvement from week 0 to 12)

  9. Remission of HDRS 17

    Time frame: Week 12

    Remission (HDRS-17 ≤ 8)

  10. Young Manic Rating Scale (YMRS)

    Time frame: Weeks 0, 1, 2, 4, 6, 8, 12

    Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events

  11. Serious adverse events

    Time frame: Up to week 12

    Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events

Other outcomes

  1. Conditioned pain modulation

    Time frame: Week 0 and 4

    Temperature of the thermode reported as painful

  2. Actigraphy

    Time frame: 1 week before treatment up to 4 weeks after finishing study

    Continuous measure (score changes).

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Collaborators

  • Brain & Behavior Research Foundation

Registry information

Official study title

Treatment of Depression in the Elderly With Repetitive Transcranial Magnetic Stimulation (rTMS) Using Theta-burst Stimulation (TBS): Randomized, Double-blind, Sham-controlled, Clinical Trial

Acronym: MrTED

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Apr 13, 2021
Registry last updated
Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.